Else Kröner-Fresenius Foundation

Home » Infrastructure » Else Kröner-Fresenius Foundation
Else Kröner (November 1974)

Else Kröner (November 1974),
© EKFS

Else Kröner-Fresenius Foundation

Who, if not us?

With these words, Else Kröner (1925–1988), a benefactor and one of Germany’s most successful entrepreneurs, expressed her commitment to dedicating herself to advancing medical progress and the health and well-being of mankind. Starting with the pharmacy ‘Hirsch-Apotheke’ in Frankfurt and a small pharmaceutical firm, she proceeded to establish Fresenius, a health-care group that is active worldwide. Upon her death, she entrusted her entire fortune to the non-profit Else Kröner-Fresenius Foundation (EKFS), which she founded in 1983.

Else Kröner (November 1974)

Else Kröner (November 1974),
© EKFS

Advancing Research. Helping People.

The Else Kröner-Fresenius Foundation is dedicated to advancing medical research and supports medical-humanitarian relief projects. To date, the foundation has funded roughly 1,900 projects. With an annual funding volume of over 50 million euros, the EKFS is one of Germany’s largest foundations and the largest German foundation that supports medicine. The EKFS receives nearly all of its income from dividends issued by the Fresenius health-care group, of which the foundation is the largest shareholder.

Medical-humanitarian Funding: Sonography training and bedside teaching are elementary components of the project “Establishment and organisation of an emergency ward at St. Francis Referral Hospital in Ifakara (Tanzania) © EKFS/Simone Utler

Medical-humanitarian Funding: Sonography training and bedside teaching are elementary components of the project “Establishment and organisation of an emergency ward at St. Francis Referral Hospital in Ifakara (Tanzania)
© EKFS/Simone Utler

eHealth network

Medical-scientific Funding: The board (upper row) and the fellows (lower row) of the Else Kröner-Forschungskolleg Dresden work in the research field of phosphoproteome dynamics to develop targeted therapies for patients with oncological, neurological and metabolic diseases.
© S Lämmle